LivaNova plc (LIVN) Tops Q1 EPS by 8c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
May 6, 2026 6:00 AM EDTDelivered double-digit reported and constant-currency revenue growth
Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)
Received U.S. Food and Drug Administration premarket approval for aura6000 System to treat moderate to severe obstructive sleep apnea
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance.
Financial Summary and Highlights(1)
First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a... More